Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

被引：1

作者：

Waddell, Tom Samuel

Chau, Ian

Peckitt, Clare

Gonzalez, David

Wotherspoon, Andrew

Patel, Bijal

Middleton, Gary William

Wadsley, Jonathan

Ferry, David

Mansoor, Wasat

Crosby, Tom David Lewis

Coxon, Fareeda Y.

Smith, David

Waters, Justin S.

Iveson, Timothy

Falk, Stephen

Slater, Sarah

Okines, Alicia Frances Clare

Cunningham, David

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Royal Marsden NHS Fdn Trust, Surrey, England

[3] St Lukes Canc Ctr, Guildford, Surrey, England

[4] Weston Pk Hosp, Sheffield, S Yorkshire, England

[5] New Cross Hosp, Wolverhampton, England

[6] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[7] Velindre Hosp NHS Fdn Trust, Cardiff, Wales

[8] Northem Ctr Canc Care, Newcastle, NSW, Australia

[9] Clatterbridge Ctr Oncol NHS Fdn Trust, Wirral, Merseyside, England

[10] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England

[11] Canc Res UK Clin Ctr, Southampton, Hants, England

[12] Bristol Haematol & Oncol Ctr, Bristol, Avon, England

[13] Barts & London NHS Trust, London, England

[14] Royal Marsden Hosp, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.4067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4067

引用

页数：1

共 37 条

[1] A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
Waddell, Tom Samuel
Chau, Ian
Barbachano, Yolanda
de Castro, David Gonzalez
Wotherspoon, Andrew
Saffery, Claire
Middleton, Gary William
Wadsley, Jonathan
Ferry, David Raymond
Mansoor, Wasat
Crosby, Tom David Lewis
Coxon, Fareeda Y.
Smith, David
Waters, Justin S.
Iveson, Timothy
Falk, Stephen
Slater, Sarah
Okines, Alicia Frances Clare
Cunningham, David
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[2] Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial
Cafferkey, C.
Smyth, E.
Loehr, A.
Harding, T.
Raponi, M.
Okines, A.
Waddell, T.
Chau, I.
Cunningham, D.
ANNALS OF ONCOLOGY, 2016, 27
[3] A RANDOMISED MULTICENTRE TRIAL OF EPIRUBICIN, OXALIPLATIN AND CAPECITABINE (EOC) plus PANITUMUMAB IN ADVANCED OESOPHAGO-GASTRIC CANCER (REAL3): UPDATED RESULTS
Waddell, T. S.
Reis-Filho, J.
Gonzalez-De-Castro, D.
Chau, I.
Wotherspoon, A.
Gupta, S.
Saffery, C.
Middleton, G.
Wadsley, J.
Cunningham, D.
ANNALS OF ONCOLOGY, 2012, 23 : 224 - 224
[4] Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Okines, Alicia F. C.
Ashley, Sue E.
Cunningham, David
Oates, Jacqueline
Turner, Andrea
Webb, Janine
Saffery, Claire
Chua, Yu Jo
Chau, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3945 - 3950
[5] REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.
Chau, I.
Okines, A. F. C.
de Castro, D. Gonzalez
Saffery, C.
Barbachano, Y.
Wotherspoon, A.
Puckey, L.
Wilson, S. Hulkki
Coxon, F. Y.
Middleton, G. W.
Ferry, D. R.
Crosby, T. D. L.
Madhusudan, S.
Wadsley, J.
Waters, J. S.
Hall, M.
Swinson, D.
Robinson, A.
Smith, D.
Cunningham, D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Waddell, Tom
Chau, Ian
Cunningham, David
Gonzalez, David
Frances, Alicia
Okines, Clare
Wotherspoon, Andrew
Saffery, Claire
Middleton, Gary
Wadsley, Jonathan
Ferry, David
Mansoor, Wasat
Crosby, Tom
Coxon, Fareeda
Smith, David
Waters, Justin
Iveson, Timothy
Falk, Stephen
Slater, Sarah
Peckitt, Clare
Barbachano, Yolanda
LANCET ONCOLOGY, 2013, 14 (06): : 481 - 489
[7] A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma
Petersen, Peter C.
Petersen, Lone N.
Vogelius, Ivan
Bjerregaard, Jon K.
Baeksgaard, Lene
ACTA ONCOLOGICA, 2021, 60 (07) : 948 - 953
[8] Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial (vol 14, pg 481, 2013)
Waddell, Tom
Chau, Ian
Cunningham, David
Gonzalez, David
Okines, Alicia Frances Clare
Wotherspoon, Andrew
Saffery, Claire
Middleton, Gary
Wadsley, Jonathan
Ferry, David
Mansoor, Wasat
Crosby, Tom
Coxon, Fareeda
Smith, David
Waters, Justin
Iveson, Timothy
Falk, Stephen
Slater, Sarah
Peckitt, Clare
Barbachano, Yolanda
LANCET ONCOLOGY, 2013, 14 (07): : E254 - E254
[9] Health-related quality-of-life (HRQoL) results from the FAST study: A phase II trial of epirubicin, oxaliplatin, and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+gastric and gastroesophageal junction adenocarcinoma.
Morlock, Robert
Turnbull, James
Blahut, Steven
Krukas-Hampel, Michelle R.
Hawryluk, Emily
Tureci, Ozlem
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[10] Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III Randomized trial
Reni, Michele
Bonetto, Elisa
Cordio, Stefano
Passoni, Paolo
Milandri, Carlo
Cereda, Stefano
Spreafico, Anna
Galli, Laura
Bordonaro, Roberto
Staudacher, Carlo
Di Carlo, Valerio
Johnson, Colin D.
PANCREATOLOGY, 2006, 6 (05) : 454 - 463

← 1 2 3 4 →